Incorporating Biologic Factors Into Breast Cancer Staging
Kelly K. Hunt, MD, professor of Surgery, and chair, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses incorporating biologic factors into breast cancer staging.
Kelly K. Hunt, MD, professor of Surgery, and chair, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses incorporating biologic factors into breast cancer staging.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
